Summary
The development of incretin-based therapies over the past decade since the approval of exenatide has opened new possibilities for the treatment of type 2 diabetes mellitus (T2DM). This article discusses the various metabolic activities of endogenous GLP-1 and DPP-4 antagonists, the side effects of incretin-based therapies, and the need for new diabetes treatments.
- Diabetes Mellitus
- Endocrinology
- Diabetes & Metabolic Syndrome
- Diabetes Mellitus
- © 2014 MD Conference Express®
Tools
Table of contents
Cited By...
- No citing articles found.